MedicalResearch.com Interview with:
[caption id="attachment_30421" align="alignleft" width="144"]

Prof. Al Brown[/caption]
Professor Alistair J P Brown DSc FSB FAAM FRSE
Aberdeen Fungal Group, MRC Centre for Medical Mycology,
University of Aberdeen, Institute of Medical Sciences,
Foresterhill, Aberdeen UK
MedicalResearch.com: What is the background for this study?
Response: Most of us harbor the yeast
Candida albicans,
and most of the time it does us no harm. However, under certain circumstances it can break out to cause nasty infections of the mouth or genitalia (thrush), or potentially fatal infections in vulnerable intensive care patients. Indeed, over half of women will suffer at least one episode of vulvovaginal candidiasis in their lifetime, and over 5% of women suffer recurrent episodes (four or more episodes per annum). Also, it has been estimated that there are over 400,000 life-threatening systemic
Candida infections worldwide per annum, of which over 40% are fatal (see
Science Translational Medicine (2012) vol. 4, 165rv13). A key to this is the potency of our immunological defenses: the weaker our defenses the more vulnerable we are to fungal infection. Therefore, we in the Medical Research Council (MRC) Centre for Medical Mycology – and other groups worldwide – are studying the mechanisms by which our immune cells recognize and kill invading
Candida cells, thereby protecting us from infection.